Binding characteristics of novel nonsteroidal antiestrogens to the rat uterine estrogen receptors.
Tamoxifen (TAM), the only antiestrogen currently available for the endocrine therapy of breast cancer behaves as a mixed agonist/antagonist of estrogen action, thus limiting its therapeutic potential. We report the binding characteristics of a novel series of nonsteroidal antiestrogens to the rat uterine estrogen receptor. As measured by competition studies, the affinity of EM-652, the active metabolite of the prodrug EM-800, for the estrogen receptor is 7-11 times higher than that of 17beta-estradiol (E2), ICI 182780, and hydroxy-tamoxifen (OH-TAM), the active metabolite of Tamoxifen. EM-652 is 20x more potent than ICI 164384 and Droloxifene while it is 400 times more potent than Toremifene in displacing [3H]E2 from the rat uterine estrogen receptor. On the other hand, the prodrug EM-800 and Tamoxifen have respectively 150-fold and 410-fold less affinity for the estrogen receptor than the pure antiestrogen EM-652. No significant binding of EM-652, EM-800, TAM or OH-TAM was observed to the rat uterine progesterone receptor at concentrations up to 10,000 nM except for TAM that caused a 50% displacement of labeled R5020 at 4000 nM. No significant binding of EM-652 or EM-800 was observed on the rat ventral prostate androgen receptor or the rat uterine progesterone receptor. The present data demonstrate the high affinity and specificity of the new antiestrogen, EM-652, for the rat uterine estrogen receptor. The antiestrogen EM-652 thus becomes the compound having the highest known affinity for the estrogen receptor. Due to its unique potency and its pure antiestrogenic activity already demonstrated in many systems, this antiestrogen could well offer an important advance for the endocrine therapy of breast cancer, uterine cancer, and other estrogen-sensitive diseases in women.
Martel
C
C
Laboratory of Molecular Endocrinology, CHUL Research Center, Quebec, Canada.
Provencher
L
L
Li
X
X
St Pierre
A
A
Leblanc
G
G
Gauthier
S
S
Mérand
Y
Y
Labrie
F
F
D000728:Androgens / Q000378:metabolism; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D001578:Benzopyrans / Q000378:metabolism; D001667:Binding, Competitive / Q000502:physiology; D004958:Estradiol / Q000031:analogs & derivatives / Q000378:metabolism; D004965:Estrogen Antagonists / Q000378:metabolism*; D005260:Female; D008297:Male; D015394:Molecular Structure; D011355:Prodrugs / Q000378:metabolism; D011397:Promegestone / Q000378:metabolism; D011422:Propionates / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D011960:Receptors, Estrogen / Q000378:metabolism*; D011980:Receptors, Progesterone / Q000378:metabolism; D013629:Tamoxifen / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology; D014599:Uterus / Q000502:physiology*
D000728:Androgens; D000970:Antineoplastic Agents; D001578:Benzopyrans; D004965:Estrogen Antagonists; D011355:Prodrugs; D011422:Propionates; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C110902:alpha-hydroxytamoxifen; D013629:Tamoxifen; D004958:Estradiol; D011397:Promegestone; C106945:EM 800